2013
DOI: 10.1002/term.1645
|View full text |Cite
|
Sign up to set email alerts
|

eNOS transfection of adipose-derived stem cells yields bioactive nitric oxide production and improved results in vascular tissue engineering

Abstract: This study evaluates the durability of a novel tissue engineered blood vessel (TEBV) created by seeding a natural vascular tissue scaffold (decellularized human saphenous vein allograft) with autologous adipose-derived stem cells (ASC) differentiated into endothelial-like cells. Previous work with this model revealed the graft to be thrombogenic, likely due to inadequate endothelial differentiation as evidenced by minimal production of nitric oxide (NO). To evaluate the importance of NO expression by the seede… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
36
1

Year Published

2014
2014
2024
2024

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 31 publications
(37 citation statements)
references
References 43 publications
0
36
1
Order By: Relevance
“…Our laboratory has extensively studied the use of these cells to create an intimal surface on a natural vascular tissue conduit (decellularized vein graft). We have previously demonstrated that ASC acquire EC characteristics after culture in either endothelial cell growth supplement or in EGM2 [8e10, 26,27]; upregulate EC-specific markers in response to shear force [9]; and remain attached to the luminal surface of a vascular scaffold using flow conditioning to promote retention of the ASC [26]. In the present study, we evaluate the creation of the graft using ASC from DM patients.…”
Section: Discussionmentioning
confidence: 94%
“…Our laboratory has extensively studied the use of these cells to create an intimal surface on a natural vascular tissue conduit (decellularized vein graft). We have previously demonstrated that ASC acquire EC characteristics after culture in either endothelial cell growth supplement or in EGM2 [8e10, 26,27]; upregulate EC-specific markers in response to shear force [9]; and remain attached to the luminal surface of a vascular scaffold using flow conditioning to promote retention of the ASC [26]. In the present study, we evaluate the creation of the graft using ASC from DM patients.…”
Section: Discussionmentioning
confidence: 94%
“…20 Human saphenous vein (Regeneration Technologies, Birmingham, Ala) was decellularized with 0.075% sodium dodecyl sulfate. 12,13 The resultant vascular scaffold (w4 cm long  w0.5 cm in diameter) was mounted within a bioreactor chamber (LumeGen system; Tissue Growth Technologies, Minnetonka, Minn) filled with EGM-2 cell culture medium (Lonza). The graft was filled with fibronectin (18 mg/mL; BD Biosciences) and incubated with rotation for 1 hour.…”
Section: Methodsmentioning
confidence: 99%
“…7,8 Our group and others have demonstrated differentiation of ASCs toward both endothelial cell (EC) and smooth muscle cell lineages. [7][8][9][10][11][12][13] We have used these cells for vascular graft creation, demonstrating success with use of autologous ASCs as EC substitutes in vivo. [7][8][9][10][11][12][13] To date, our work has used standard culture techniques involving supplementation of the medium with fetal bovine serum (FBS).…”
mentioning
confidence: 98%
“…Many studies have confirmed the adipose-derived stromal cells (ASC) potential for multilineage differentiation as well as their low immunogenicity [15][16][17][18][19]. More recently, ASC have also been investigated in the context of vascular tissue engineering [16,[20][21][22]. Indeed, given ASC's differentiation capabilities, they were evaluated both as an EC source to form an endothelium-like monolayer in grafts lumen; or as a SMC source to seed vascular scaffolds.…”
Section: Introductionmentioning
confidence: 95%
“…Indeed, given ASC's differentiation capabilities, they were evaluated both as an EC source to form an endothelium-like monolayer in grafts lumen; or as a SMC source to seed vascular scaffolds. Among the research groups using ASC to replace the endothelium, some have seeded grafts with undifferentiated ASC and used them as is [23]; while most have differentiated ASC toward endothelial cell lineage in vitro before or after grafts' seeding [21,24]. Although one advantage of the use of ASC over mature EC to endothelialize vascular grafts relies on their ease of harvest and availability, the time required for differentiation and the suboptimal functionality of the resulting endothelial-like cells may counteract this advantage.…”
Section: Introductionmentioning
confidence: 96%